Orphan Drugs: FDA February 2015 Approvals
The chart below identifies Orphan Drugs receiving FDA February 2015 approval as of 03/12/15 in ascending “Approval Date” order.
FDA February 2015 Orphan Products Receiving Approval
|#||Generic Name/Approval Date||Sponsor Company||Indication|
|1||Lenvatinib (Lenvima)/ 02.13||Eisai||Recurrent/metastatic/ progressive radioactive iodine refractory differentiated thyroid cancer|
|2||Panobinostat (Farydak)/ 02.23||Novartis||Multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent|
Copyright © 2012-2015, Orphan Druganaut Blog. All rights reserved.